ArticleBMC pediatrics2025
Determinants of physical activity level in pediatric oncological patients treated with cardiotoxic therapy - a study protocol.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06256068 (Determinants of Physical Activity Level in Pediatric Oncological Patients Treated With Cardiotoxic Therapy - a Study Protocol), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Determinants of Physical Activity Level in Pediatric Oncological Patients Treated With Cardiotoxic Therapy - a Study Protocol
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood cancer and its therapy, especially that involving potentially cardiotoxic cancer treatment, can structurally affect muscle strength and heart function, and therefore may result in lowered physical activity (PA). This study protocol aims to find the significant determinants of PA levels in pediatric oncological patients 1-5 years after heart-toxic chemotherapy and/or radiation of the heart region.
methodsThe study group will include children 1-5 years after completing cancer therapy involving cardiotoxicity risk factors. The primary outcome of interest is the PA measured with an ActiGraph GT3X Accelerometer for 14 consecutive days and the assessment of WHO pediatric age-adjusted PA norms achievement. Assessed PA levels will be evaluated according to the possible determinants of PA: disease/treatment related risk factors, treatment complications, possible complications after the treatment, cardiac function with echocardiography including 2D and 3D strain imaging, physical function and muscle strength in ALPHA (Assessing Levels of Physical Activity) health-related fitness test battery and exercise capacity in cardiopulmonary exercise testing. The self-efficacy and motivation to PA, quality of life (QoL), lifestyle, socio-demographic, and anthropogenic factors as well as knowledge about the positive impact of PA will be evaluated with original and validated questionnaires. The PA determinants of the study group will be compared to the results of the control group of children in the same follow-up period (> 1 year < 5 years) after completing cancer therapy without cardiotoxic methods. DISCUSSION: The results may contribute to the development of future recommendations on prophylactic and therapeutic approaches, as well as proper lifestyle recommendations for children in long-term follow-up after cardiotoxic cancer therapy. The determinants will be used to develop targeted exercise prescriptions and exercise programs.
trial registrationNCT06256068.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.